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EXPERIMENTAL STUDIES
Simvastatin Preserves Myocardial Perfusion and
Coronary Microvascular Permeability in Experimental
Hypercholesterolemia Independent of Lipid Lowering
Piero O. Bonetti, MD,* Stephanie H. Wilson, MBBS,* Martin Rodriguez-Porcel, MD,*
David R. Holmes, JR, MD, FACC,* Lilach O. Lerman, MD, PHD,† Amir Lerman, MD, FACC*
Rochester, Minnesota
OBJECTIVES This study was designed to assess the lipid-independent effects of simvastatin on myocardial
perfusion (MP) and coronary microvascular permeability index (PI) at baseline and during
episodes of increased cardiac demand in experimental hypercholesterolemia.
BACKGROUND Simvastatin preserves coronary endothelial function in experimental hypercholesterolemia
independent of its lipid-lowering effect. However, the functional significance of this
observation is unknown.
METHODS Pigs were randomized to three groups: normal diet (N), high-cholesterol diet (HC) and HC
diet plus simvastatin (HCS) for 12 weeks. Subsequently, cardiac electron beam computed
tomography was performed before and during intravenous infusion of adenosine and
dobutamine, and MP and PI were calculated.
RESULTS Total and low density lipoprotein cholesterol levels were similarly and significantly increased
in HC and HCS animals compared with N. Basal MP was similar in all groups. Myocardial
perfusion significantly increased in response to either adenosine or dobutamine in N and
HCS animals. Dobutamine also significantly increased MP in HC animals. However, the
changes of MP in response to either drug were significantly lower in the HC group compared
with the other two groups (p  0.01 for adenosine and p  0.05 for dobutamine vs. N and
HCS). Basal PI was similar in all groups and was not altered by either drug in N and
HCS animals. In contrast, PI significantly increased in HC pigs during infusion of either
adenosine (p  0.001) or dobutamine (p  0.05).
CONCLUSIONS These findings demonstrate that chronic administration of simvastatin preserves myocardial
perfusion response and coronary microvascular integrity during cardiac stress in experimental
hypercholesterolemia independent of lipid lowering. (J Am Coll Cardiol 2002;40:546–54)
© 2002 by the American College of Cardiology Foundation
Several large-scale trials have demonstrated that 3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitors, com-
monly referred to as statins, significantly reduce cardiovas-
cular morbidity and mortality in patients with a wide range
of cholesterol levels (1–5). Plaque regression induced by
cholesterol reduction alone is not considered sufficient to
explain the striking benefit in these patients (6). Indeed,
recent evidence suggests that statins exert a multiplicity of
favorable effects on the vascular system that are not directly
related to their impact on lipid metabolism. These pleiotro-
pic properties may contribute to the observed benefit in
coronary artery disease beyond the reduction of cholesterol
levels (7).
Hypercholesterolemia is associated with the development
of coronary endothelial dysfunction (8), which is character-
ized by impaired endothelium-dependent vasorelaxation (9)
and an increase in microvascular permeability (10). We
recently demonstrated that changes in coronary vascular
function associated with hypercholesterolemia in a porcine
model may also lead to an attenuated increase in myocardial
perfusion (MP) and an exaggerated augmentation of coro-
nary microvascular permeability in response to an intrave-
nous infusion of adenosine (11). In humans with coronary
artery disease, altered endothelial function contributes to
ischemic manifestations and also unfavorably modulates the
course of acute coronary syndromes (12). Moreover, endo-
thelial dysfunction of the coronary resistance vessels is
associated with myocardial ischemia (13) and an adverse
prognosis (14), even in the absence of obstructive coronary
artery disease. Cholesterol lowering with statins improves
endothelial function in hypercholesterolemia (15), and is
also associated with an improvement of MP (16) in patients
with coronary artery disease. Recently, we demonstrated
that preservation of endothelial function of epicardial cor-
onary arteries and coronary arterioles in experimental hy-
percholesterolemia is one of the statin effects mediated at
least partly by lipid-independent mechanisms (17). How-
ever, the functional significance of this lipid-independent
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effect of statins on MP and coronary microvascular perme-
ability remains unclear.
The current study was designed to test the hypothesis
that chronic administration of simvastatin would preserve
MP response and coronary microvascular integrity during
situations of increased myocardial demand in an animal
model of porcine experimental hypercholesterolemia in vivo
independent of lipid lowering. For this purpose, we used
electron beam computed tomography (EBCT), an ultrafast
computed tomography technique that has been shown to
enable accurate quantification of global and regional MP
and coronary microvascular permeability in animals as well
as in humans (11,18–22).
METHODS
Animals. All the study procedures were designed in accor-
dance with the National Institutes of Health Guidelines and
approved by the Mayo Foundation Institutional Animal
Care and Use Committee. Eighteen female domestic cross-
bred pigs, three months of age, were used for the experi-
ments. These were randomized into three groups and
subsequently treated for 12 weeks: group 1 (N group; n 6)
was fed a normal diet. Group 2 (HC group; n  6) was
placed on an atherogenic diet of 2% cholesterol and 15%
lard by weight (TD 93296, Harlan Teklad, Madison,
Wisconsin). In addition to a high-cholesterol diet, animals
of group 3 (HCS group; n  6) orally received simvasta-
tin, 40 to 80 mg/d. This dosage was based on our previous
study (17) and on clinical practice in humans. Plasma lipid
profiles (Roche, Nutley, New Jersey) and in vivo studies
were performed after 12 weeks.
EBCT studies. Electron beam computed tomography
studies were performed as previously described (11,18–24).
In brief, animals were anesthetized with ketamine (30
mg/kg) and xylazine (5 mg/kg). Anesthesia was maintained
with a constant infusion of ketamine (0.3 mg/kg/min) and
xylazine (0.04 mg/kg/min) in saline. Animals were intu-
bated and ventilated with room air. The carotid artery and
the jugular vein were exposed by cutdown and cannulated
with 8F and 7F sheaths, respectively. After injection of
10,000 U of heparin intravenously and initiation of a
continuous intravenous infusion of 1,000 U heparin per
hour, a guiding catheter was placed in the descending aorta
for online blood pressure measurement and a pigtail catheter
was placed in the right atrium for injection of contrast
media.
Subsequently, animals were positioned supine in the
EBCT (Imatron C-150, Imatron Inc., South San Francisco,
California) gantry and an intravenous infusion of saline (5
ml/min) was initiated. With localization scans, cross-
sectional images at two adjacent mid-left ventricle levels
were identified. After a right atrial bolus injection (0.3
ml/kg over 2 s) of nonionic, low-osmolar contrast media
iopamidol (Isovue-370, Squibb Diagnostics, Princeton,
New Jersey), 40 consecutive electrocardiogram (ECG)-
triggered end-diastolic scans were obtained over the prese-
lected levels at one to three heartbeat intervals. Ten minutes
after this baseline study an intravenous infusion of adeno-
sine (400 g/kg/min) was started and after hemodynamic
stabilization EBCT flow studies were repeated. Subse-
quently, adenosine infusion was discontinued and ECG-
triggered cine CT images of the heart were acquired during
central venous injection of contrast agent at rest for the
determination of left ventricular volumes and left ventricular
muscle mass (LVMM). Finally, an intravenous infusion of
dobutamine (5 to 25 g/kg/min, to achieve a heart rate of
150 beats/min) was started and EBCT flow studies were
repeated after hemodynamic stabilization.
EBCT data analysis. The methods have been previously
described in detail (11,18–25). In brief, EBCT images were
transferred to a Sun workstation and regions of interest were
traced in the anterior wall and chamber of the left ventricle
using the image analysis software package Analyze (Bio-
medical Imaging Resource, Mayo Foundation, Rochester,
Minnesota), and time-density curves were generated for
both regions. The left ventricular curve was fitted with a
standard gamma-variate curve-fit, whereas the curve ob-
tained from the anterior wall was fitted using a custom-
designed extended gamma-variate curve-fitting algorithm
implemented in commercially available computer software
(KaleidaGraph, Synergy Software, Reading, Pennsylvania)
to obtain curves representing intramyocardial distribution of
contrast media in both the intra- and extravascular com-
partments (11,25). The areas enclosed under the intravas-
cular myocardial and left ventricular cavity curves were
subsequently used to calculate an index of intramyocardial
mean transit time(s) and vascular blood volume (ml/cc
tissue). Myocardial perfusion (ml/g/min) was then com-
puted as: 60  (blood volume/mean transit time)/[1.05 
(1  blood volume)]. The factor (1  blood volume) served
to correct for dynamic changes in blood volume occurring in
the heart in vivo (19–21,25). Coronary microvascular per-
meability index (PI) (arbitrary units) was calculated as
contrast extraction rate/blood volume, where contrast ex-
traction rate (analogous to permeability-surface area prod-
uct) was derived from the curve depicting the extravascular
compartment of the contrast agent as 60  1.05 
Abbreviations and Acronyms
EBCT  electron beam computed tomography
ECG  electrocardiogram
HC  hypercholesterolemia
HCS  hypercholesterolemia and simvastatin therapy
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LVEF  left ventricular ejection fraction
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LVESV  left ventricular end-systolic volume
LVMM  left ventricular muscle mass
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(maximal slope of ascending part of extravascular curve 
mean transit time)/area under left ventricular curve (11).
By using commercially available software (Imatron Inc.,
South San Francisco, California), left ventricular end-
diastolic and end-systolic frames were visually identified
from each cine-mode movie that spanned the cardiac cycle
at the level. Left ventricular volumes were measured by
planimetry from the left ventricular apex to the left ventric-
ular base and the tomographic measurements of end-
diastolic and end-systolic volume at each level were added
by use of a modified Simpson’s formula to determine left
ventricular end-diastolic (LVEDV) and end-systolic
(LVESV) volumes. Stroke volume was then calculated as
LVEDV  LVESV, cardiac output as stroke volume 
heart rate, and left ventricular ejection fraction (LVEF) as
stroke volume/LVEDV (19,24). In addition, left ventricular
myocardial area on each end-diastolic frame was measured
by planimetry after tracing the outer border of the left
ventricular myocardium, and the mass of each short-axis
slice was calculated as the product of the myocardial area,
scan slice thickness (0.8 cm) and specific gravity of the
myocardium (1.05 g/cm3). Left ventricular muscle mass was
then computed as the sum of the masses of the individual
scanned sections according to a modified Simpson’s formula
(19,23).
Statistical analysis. Results are expressed as mean SEM.
Comparisons within groups were performed using paired
Student t test. One-way analysis of variance followed by the
Bonferroni t procedure, if indicated, was used for compar-
isons among the three different groups. All analyses were
done by using SigmaStat statistical software, version 2.03
(SPSS Inc., Chicago, Illinois). Statistical significance was
accepted for a value of p  0.05.
RESULTS
Plasma lipid profiles. After 12 weeks of high cholesterol
diet, total cholesterol, low density lipoprotein (LDL) cho-
lesterol and high density lipoprotein (HDL) cholesterol
levels were significantly increased in the HC group and the
HCS group compared with pigs fed a normal diet. The
differences between the two groups fed a high-cholesterol
diet were not significant (p  0.91, p  0.78, and p  1 for
total, LDL and HDL cholesterol), indicating that simva-
statin had no lipid-modulating effect. In contrast, triglycer-
ide levels were similar in all experimental groups after the
12-week study period (Table 1).
Body weight and systemic hemodynamics. After the 12-
week study period body weight was similar in all three
experimental groups. Basal mean arterial pressure (MAP)
and basal heart rate did not differ significantly between the
groups (p  0.11 and p  0.12, respectively). Adenosine
infusion led to a significant and similar decrease in MAP,
which was associated with a significant increase in heart rate
in all experimental groups. As intended, dobutamine infu-
sion was associated with a significant increase in heart rate,
whereas it did not affect MAP. There was no significant
difference of LVEF, cardiac output or LVMM between the
different groups (Table 2).
Myocardial perfusion. Basal MP of the anterior wall was
similar in all three groups (p 0.74). Intravenous adenosine
infusion led to a significant increase in MP in normal pigs
that was not observed in HC pigs. In contrast, in HCS
pigs the MP response to adenosine was normalized. Relative
change of MP in response to adenosine was similar in the N
and the HCS groups and significantly differed from that
in the HC group (Fig. 1). Intravenous dobutamine led to a
significant increase in MP in all experimental groups.
However, the increase was more pronounced in the N and
the HCS groups compared with the HC group. Conse-
quently, similar to adenosine, the relative change of MP
during dobutamine infusion observed in the N and the
HCS groups was significantly higher than that in the HC
group (Fig. 2).
Coronary microvascular permeability. Under basal condi-
tions coronary microvascular PI did not differ substantially
among the experimental groups (p  0.42). Intravenous
adenosine infusion did not alter coronary microvascular PI
in the N group, but led to a significant increase in this
parameter in the HC group. However, similar to normals,
no change in coronary microvascular PI in response to
adenosine was observed in the HCS group. Compared
with N and HCS animals, the relative change of coronary
microvascular PI in response to adenosine was significantly
Table 1. Plasma Lipid Profiles in the Three Experimental
Groups at 12 Weeks
N HC HCS
Total cholesterol, mg/dl 79  4 379  71* 464  67*
LDL cholesterol, mg/dl 34  4 276  67* 362  60*
HDL cholesterol, mg/dl 39  3 95  7* 98  13*
Triglycerides, mg/dl 26  4 45  9 23  4
Values are mean  SEM. *p  0.05 vs. N.
HC  hypercholesterolemic pigs; HCS  hypercholesterolemic pigs receiving
simvastatin; HDL  high density lipoprotein; LDL  low density lipoprotein; N 
normocholesterolemic pigs.
Table 2. Body Weight and Systemic Hemodynamics in the
Three Experimental Groups at 12 Weeks
Normal HC HCS
Body weight, kg 61  2 61  2 59  2
MAP, mm Hg
Baseline 111  4 112  7 94  7
Adenosine 101  4* 91  8* 83  6*
Dobutamine 105  7 114  15 103  10
Heart rate, beats/min
Baseline 75  4 68  6 85  7
Adenosine 88  5* 79  5* 96  6*
Dobutamine 156  3† 153  1† 157  5†
LVEF, % 55  1 58  2 59  1
Cardiac output, l/min 4.4  0.2 4.2  0.5 4.7  0.7
LVMM, g 103.1  3.3 108.9  3.8 104.4  4.6
Values are mean  SEM. *p  0.05 vs. baseline; † p  0.001 vs. baseline.
HC  hypercholesterolemic pigs; HCS  hypercholesterolemic pigs receiving
simvastatin; LVEF  left ventricular ejection fraction; LVMM  left ventricular
muscle mass; MAP  mean arterial pressure; N  normocholesterolemic pigs.
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increased in HC animals (Fig. 3). Similar to adenosine,
intravenous infusion of dobutamine was associated with a
significant increase in coronary microvascular PI only in the
HC group, but not in the N or the HCS group. The
relative change of this parameter in response to dobutamine
in HC pigs significantly differed from that in N pigs,
whereas the magnitude of the microvascular permeability
response in HCS animals was similar to that in N animals
(Fig. 4).
DISCUSSION
The current study demonstrates that simvastatin prevents
the attenuation of the MP response and the increase in
coronary microvascular permeability during cardiac stress
associated with experimental hypercholesterolemia, inde-
pendent of any lipid-lowering effect.
Assessment of pleiotropic effects of statins in vivo.
Statins have been shown to significantly reduce morbidity
and mortality from coronary events in patients with a wide
range of cholesterol levels (1–5). It is now clear that the
clinical benefit of statins cannot be attributed to cholesterol
lowering alone and that these drugs exert pleiotropic effects
that clearly are independent of their impact on cholesterol
levels (7). However, despite growing knowledge about
numerous lipid-independent properties of this class of drugs
in vitro, little is known about their consequences in vivo.
One of the problems in identifying lipid-independent effects
of statins in vivo is differentiating them from the indirect
effects related to lipid lowering. Another confounding factor
is that a direct effect of a statin may complement an indirect
effect (26). In accordance with one of our previous studies
(17), simvastatin did not alter plasma cholesterol levels in
our animal model of dietary hypercholesterolemia, which may
be attributable to the pure dietary nature of hypercholesterol-
emia in our model and the fact that lipid-lowering potency and
efficacy of statins are much lower in pigs than in humans
(27). Hence, our animal model provides a unique opportu-
nity to study lipid-independent effects of statins in vivo.
Figure 1. (Upper) Anterior wall myocardial perfusion at baseline and in response to intravenous adenosine in the three experimental groups. (Lower)
Relative change of anterior wall myocardial perfusion in response to intravenous adenosine in the three experimental groups (compared to baseline). HC
hypercholesterolemic pigs; HCS  hypercholesterolemic pigs receiving simvastatin; N  normocholesterolemic pigs. *p  0.01 versus N and HCS.
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Effect of simvastatin on MP. Our animal model of hy-
percholesterolemia has been well characterized and shows
endothelial dysfunction of epicardial coronary arteries and
coronary resistance vessels (17), without development of
atherosclerotic plaques (28). Hence, the observed difference
of increase in MP during simulated cardiac stress between
untreated hypercholesterolemic pigs and those treated with
simvastatin cannot be attributed to the presence of coronary
stenoses or an inhibitory effect of simvastatin on the
development of such lesions.
Several mechanisms may be responsible for the observed
differences of the MP response to simulated cardiac stress
between the experimental groups. The hemodynamic effects
of dobutamine result from a unique and complex interaction
of its alpha- and betamimetic properties (29). However,
although dobutamine may have a minor direct vasodilative
effect on coronary vessels, the increase in myocardial blood
flow in response to this compound is due mainly to
enhanced myocardial metabolic demand, which leads to
dilation and/or recruitment of coronary resistance vessels,
including arterioles that are 100 m in diameter. Impor-
tantly, endothelium-derived NO has been shown to play a
pivotal role for the dilative response of the coronary micro-
vasculature associated with the infusion of dobutamine (30).
Thus, the increase in MP in response to dobutamine
depends to a certain degree on endothelial function. On the
other hand, adenosine is primarily considered an
endothelium-independent vasodilator. However, its vasodi-
latory effect is mediated via specific A2-receptors that are
located not only on vascular smooth muscle cells but also on
endothelial cells (31,32). Moreover, several studies demon-
strated that the vasorelaxant effect exerted by adenosine
involves the release of NO (33,34), and is, therefore, also
somewhat dependent on endothelial function. Thus,
changes in endothelial function may play a role in the
vasodilatory response to both dobutamine and adenosine.
Furthermore, we recently demonstrated that treatment with
simvastatin preserves endothelial function in epicardial ar-
teries and resistance vessels in vitro in a lipid-independent
manner (17). Hence, although direct effects of dobutamine
and adenosine might have contributed to our results, it is
likely that the lack of increase in MP during infusion of
either drug observed in hypercholesterolemic pigs might
result from coronary endothelial dysfunction, and that the
Figure 2. (Upper) Anterior wall myocardial perfusion at baseline and in response to intravenous dobutamine in the three experimental groups. (Lower)
Relative change of anterior wall myocardial perfusion in response to intravenous dobutamine in the three experimental groups (compared to baseline). HC
hypercholesterolemic pigs; HCS  hypercholesterolemic pigs receiving simvastatin; N  normocholesterolemic pigs. *p  0.05 vs. N and HCS.
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normalization of MP in animals treated with simvastatin is
the result of preservation of endothelial function. In this
context, our results are in accordance with a previous clinical
study reporting a reduction of episodes of transient myo-
cardial ischemia with pravastatin in patients with coronary
artery disease and normal to moderately elevated serum
cholesterol (35). These investigators speculated that the
anti-ischemic effect of pravastatin in their study was mainly
mediated by a normalization of coronary endothelial func-
tion, because an angiographic study in the same patient
population demonstrated only less progression but not
regression of preexisting coronary atherosclerosis with pra-
vastatin therapy (36). Our current study extends these
previous observations and demonstrates that the beneficial
effects of simvastatin upon MP are not only independent of
lipid lowering, but also occur very early in the course of
atherogenesis, even before obvious morphologic alterations
of the vessel wall are present (28).
Effect of simvastatin on coronary microvascular perme-
ability. The demonstrated changes of coronary microvas-
cular permeability among the different experimental groups
further support the hypothesis that simvastatin exerts its
benefits upon MP primarily by its endothelial-protective
actions. Increased microvascular permeability is a character-
istic feature of endothelial dysfunction and is considered a
major pathogenetic mechanism in atherogenesis (10). In
accordance with our previous findings (11), we found that
coronary microvascular permeability, though normal under
basal conditions, significantly increased during simulated
cardiac stress in hypercholesterolemic pigs. On the other
hand, this abnormal alteration of vascular permeability was
prevented in animals fed a high-cholesterol diet and simul-
taneously treated with simvastatin. Again, this effect of
simvastatin was independent of any change in plasma lipid
levels. These results are in line with a recently published
study demonstrating a normalization of increased microvas-
cular permeability with simvastatin therapy in hypercholes-
terolemic men (37). Although the relationship between
endothelial dysfunction and functionally increased vascular
permeability is established, other factors that might influ-
ence vessel wall permeability must also be considered. In an
earlier study we have demonstrated that experimental hy-
percholesterolemia is associated with ultrastructural changes
of the internal elastic lamina in epicardial coronary arteries
Figure 3. (Upper) Anterior wall microvascular permeability index at baseline and in response to intravenous adenosine in the three experimental groups.
(Lower) Relative change of anterior wall microvascular permeability index in response to intravenous adenosine in the three experimental groups (compared
to baseline). HC  hypercholesterolemic pigs; HCS  hypercholesterolemic pigs receiving simvastatin; N  normocholesterolemic pigs. *p  0.001 vs.
N and HCS.
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(38). Thus, these structural alterations of the vessel wall
might contribute to changes in vascular permeability, and
the underlying mechanism for the effect of statins on
microvascular permeability might also be secondary to the
modification of compartments of the vessel wall other than
the endothelium.
Suggested mechanism. We recently demonstrated that
adverse changes of MP and coronary microvascular perme-
ability in hypercholesterolemia such as those observed in the
present study might be mediated by an increase in oxidative
stress (11). Moreover, we have shown that simvastatin may
reduce oxidative stress (17). Therefore, it may be speculated
that the beneficial effects exerted by simvastatin are at least
partly mediated by its antioxidant effects.
Pharmacologic stress tests in pigs. The magnitude of the
MP response to intravenous dobutamine in normal animals
was similar to that observed in healthy humans and pigs
(39,40). On the other hand, although clearly significant, the
increase in MP in response to intravenous adenosine in
normal animals was less than that observed in previous
studies in humans using intracoronary Doppler flow mea-
surements (41). Several EBCT studies employing venous
injections of contrast media reported underestimation of
absolute MP at high flow rates induced by coronary vaso-
dilators such as adenosine (22). Reasons postulated for these
observations included failure to correct for intramyocardial
vascular volume, which increases in relation to myocardial
blood flow, and the use of intravenous (rather than intraaor-
tic) injections of contrast, which results in spread of the
bolus (22). In the present study, changes in intramyocardial
vascular volume during adenosine infusion were taken into
account for calculation of MP, and thus a major confound-
ing effect by this variable is unlikely. However, we cannot
exclude the possibility that the duration of the arterial input
curve (left ventricular cavity curve) exceeded coronary transit
time in the high flow state induced by adenosine and led to
some underestimation of absolute MP. This may account
for the moderate, though significant, increase in MP in
response to adenosine in normal animals. Interestingly,
however, intravenous administration of contrast did not
substantially decrease MP reserve to intravenous adenosine
in humans when EBCT methodology similar to the current
study and a correction for changes in intramyocardial
vascular volume were used (22). Hence, and because the
Figure 4. (Upper) Anterior wall microvascular permeability index at baseline and in response to intravenous dobutamine in the three experimental groups.
(Lower) Relative change of anterior wall microvascular permeability index in response to intravenous dobutamine in the three experimental groups
(compared to baseline). HC  hypercholesterolemic pigs; HCS  hypercholesterolemic pigs receiving simvastatin; N  normocholesterolemic pigs.
*p  0.05 vs. N.
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EBCT-derived MP reserve to dobutamine was not attenu-
ated, species variability in the response to intravenous
adenosine might have contributed to the relatively moderate
MP reserve observed in normal animals.
Conclusions. In summary, this study demonstrates that
simvastatin preserves MP response and coronary microvas-
cular integrity during situations of cardiac stress in experi-
mental hypercholesterolemia independent of lipid lowering.
These results contribute to the growing evidence that statins
exert their beneficial effects to a considerable part in a
lipid-independent manner.
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